Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors

Journal of Nuclear Medicine

Volumn 39, Issue 5, 1998, Pages 810-815

  Kole, Annemieke C ^a   Nieweg, Omgo E ^b   Hoekstra, Harald J ^b   Van Horn, James R ^b   Koops, Heimen Schraffordt ^b   Vaalburg, Willem ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Bone neoplasms; Fluorine 18 fluorodeoxyglucose; Glucose metabolism; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; BONE TUMOR; CHONDROSARCOMA; CLINICAL ARTICLE; EWING SARCOMA; FEMALE; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; BONE AND BONES; BONE NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; RADIOPHARMACEUTICALS; ROC CURVE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031955945     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
2. Leskinen-Kallio S. Positron emission tomography in oncology. Clin Physiol 1994;14: 329-335.
3. Shields AF, Graham MM, Spence AM. The role of PET imaging in clinical oncology. A current status report. In: Freeman LM, ed. Nuclear medicine annual. New York: Raven Press; 1995:129-168.
4. Jones T. The imaging science of positron emission tomography. Eur J Nucl Med 1996;23:807-813.
5. Lamki LM. Positron emission tomography in oncology. Cancer 1996;78:2039-2042.
6. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988:29:181-186.
7. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992;182:185-194.
8. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculosketetal tumors using PET. J Nucl Med 1991;32:1508-1512.
9. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996:37:257-261.
10. l8F-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
11. 11C]-tyrosine PET in patients with breast cancer. J Nucl Med 1997;38:692-696.
12. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
13. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
14. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1996;200:243-247.
15. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974;291: 1041-1046.
16. Woolfenden JM, Pitt MJ, Durie BGM, Moon TE. Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology 1980;134:723-728.
17. Sasaki M, Ichiya Y, Kuwabara Y, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in technetium-99m-hydroxymethylenediphosphate negative bone tumors. J Nucl Med 1993;34:288-290.
18. Vieras F, Herzberg DL. Focal decreased skeletal uptake secondary to metastatic disease. Radiology 1976;1118:121-122.
19. Warburg O. The metabolism of tumors. New York: Richard R. Smith; 1931:129.
20. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993;72:2979-2985.
21. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of glucose transporter gene. J Biol Chem 1988;27:13655-13662.
22. Kornblith PL, Cummings CJ, Smith BH, Brooks RA, Patronas NJ, Di Chiro G. Correlation of experimental and clinical studies of metabolism by PET scanning. Prog Exp Tumor Res 1984;27:170-178.
23. Lowry OH, Berger SJ, Carter JG, et al. Diversity of metabolic patterns in human brain tumors: enzymes of energy metabolism and related metabolites and cofactors. J Neurochem 1983;41:994-1010.
24. Fradkin SZ, Zhavrid EA, Nebyshinskaia NS, Istomin IuP. Induced hyperglycemia as a factor of modification of sarcoma 45 sensitivity to chemotherapy [English Abstract]. Eksp Onkol 1987;9:64-68.
25. Krimker VM, Goldobenko GV, Ozhiganov EL, Aitakova TI, Diuskaliev ZhD. The use of artificial hyperglycemia in the radiotherapy of patients with rectal cancer [English Abstract]. Eksp Onkol 1986;32:40-46.
26. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992;11:445-456.
27. Van Ginkel RJ, Hoekstra HJ, Pruim J, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 1996;37:984-990.
28. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1995;196:647-655.
29. Brudin LH, Valind SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994;21: 297-305.
30. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi T, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.
31. Kransdorf MJ, Sweet DE. Aneurysmal bone cyst: concept, controversy, clinical presentation, and imaging. Am J Roentgenol 1995;164:573-580.
32. Schajowicz F, Lemos C. Osteoid osteoma and osteoblasloma: closely related entities of osteoblastic derivation. Acta Orthop Scand 1970;41:272-291.
33. Crim JR, Mirra JM, Eckardt JJ, Seeger LL. Widespread inflammatory response to osteoblastoma: the flare phenomenon. Radiology 1990;177:835-836.
34. 18F]FDG-PET [Abstract], Eur J Nucl Med 1996;23:1104.